在认知障碍的老年人中Ruminococcus gnavus的作用:病例对照研究和动物实验
Yanfei Wei1, Yining Huang1, Shiao Wang1
1Department of Epidemiology, School of Public Health (Guangdong Provincial Key Laboratory of Tropical Disease Research), Southern Medical University, Guangzhou, China.
Journal of Alzheimer's disease : JAD
|September 1, 2025
概括
肠道细菌Ruminococcus gnavus与老年人的认知障碍 (CI) 有关. 这种微生物可能会抑制细胞自的关键过程, 可能会导致神经退行和阿尔茨海默病的风险.
科学领域:
- 微生物学
- 神经科学
- 胃肠病学
背景情况:
- 认知障碍 (CI) 是老年人患阿尔茨海默病 (AD) 的重要危险因素.
- 肠-大脑轴及其相关的微生物群在神经退行过程中发挥着关键作用.
- 肠道微生物的自调节是影响认知功能的潜在机制.
研究的目的:
- 研究Ruminococcus gnavus与老年人的认知障碍之间的关联.
- 探索与自相关的机制在R. gnavus介导的认知影响中的作用.
- 提供R. gnavus参与阿尔茨海默病相关认知衰退的证据.
主要方法:
- 在有CI和没有CI的老年人中比较便16SrRNA测序.
- 用R. gnavus对伪无细菌老鼠进行单一殖民.
- 使用莫里斯水迷宫评估认知表现.
- 通过qPCR,西红斑,组织学和ELISA分析自标志物.
- 不针对的代谢学来识别受影响的途径.
主要成果:
- 发现Ruminococcus gnavus在CI患者中具有丰富性,与认知评分相反相关.
- 被R. gnavus殖民的小鼠表现出学习和记忆障碍.
- 自食性被抑制在小鼠中,主要自食性相关基因 (例如Atg5,Beclin-1,LC3b) 的mRNA和蛋白质水平降低,P62增加.
- 代谢学发现了糖脂代谢的破坏和自途径的丰富.
结论:
- 在老年人中,R. gnavus的丰富与认知障碍有关.
- 自食可能是关键的媒介,通过肠-大脑轴将R. gnavus与认知衰退联系起来.
- 需要进一步的纵向研究来确定因果关系.
更多相关视频
07:07Analysis of Learning and Memory Ability in an Alzheimer's Disease Mouse Model using the Morris Water Maze
Published on: October 29, 2019
19.4K
09:45Motor and Hippocampal Dependent Spatial Learning and Reference Memory Assessment in a Transgenic Rat Model of Alzheimer's Disease with Stroke
Published on: March 22, 2016
10.3K
相关概念视频
Alzheimer's Disease: Overview
666
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
666
Alzheimer's Disease: Treatment
260
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
260
